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INTRODUCTION
von Hippel-Lindau (VHL) disease (MIM#193300) is a
rare, dominantly inherited disease characterized by predis-
position to the development of a combination of benign and
malignant tumors affecting multiple organs including cen-
tral nervous system, kidney, pancreas, adrenal gland, eye and
endolymphatic sac (1-5). Reported birth incidence ranges
from 1:36,000 to 1:45,000 (6). Penetrance is essentially com-
plete at 65 yr of age and subjects at risk may develop a com-
bination of clinical manifestations during their lifetime (7).
Predisposition to VHL disease results from germline muta-
tions in the VHL tumor suppressor gene, while loss of the
wild type VHL allele or inactivating mutations are addition-
ally found in tumors, either malignant (renal cell carcino-
mas, RCCs) or benign (cerebellar hemangioblastoma [HB]
or pheochromocytoma [PH]) (8). The VHL gene was mapped
to 3p25-26 (9) and cloned in 1993 by an international coop-
erative study (10). Several groups in North America, Europe,
and Japan have collectively reported more than 224 distinct
intragenic germline mutations (HGMD online), although
the frequency of mutation detection has varied considerably
among studies (11-17). The spectrum of known mutations
in the VHL gene includes missense and nonsense mutations,
deletions or insertions of one to several nucleotides, splice
site mutations, and rearrangements consisting of partial or
complete deletion of the gene. Previous studies showed a
frequency of point mutation detected by sequencing the VHL
gene of 60-80% and large deletion of the VHL gene includ-
ing partial and complete gene deletion of 20-40% in the
VHL families (18, 19). Southern blotting has been the most
conventional technique used for the detection of large dele-
tion of the VHL gene. However, it was labor intensive and
time-consuming.
Recently, a new technique, multiple ligation-dependent
probe amplification (MLPA), has been described that allows
detection of large genetic rearrangements by simultaneous
amplification of up to 45 target sequences (20, 21). Here,
we report the nature of VHL gene mutations in Korean VHL
patients. The aim of this study is to estimate the frequencies
of point mutations and large deletions missed by sequencing
analysis in Korean VHL patients and verify the usefulness of
the MLPA technique in the diagnosis of VHL. 
MATERIALS AND METHODS
Subjects
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Improved Detection of Germline Mutations in Korean VHL Patients by
Multiple Ligation-dependent Probe Amplification Analysis
von Hippel-Lindau (VHL) disease is an autosomal dominant inherited tumor syn-
drome characterized by the development of tumors in the eye, brain, spinal cord,
inner ear, adrenal gland, pancreas, kidney, and epididymis, associated with germline
mutations in the VHL gene. We used sequentially sequencing method and multi-
ple ligation-dependent probe amplification (MLPA) analysis and detected germline
mutations in the VHL in 15/15 (100%) of VHL patients fulfilling the clinical criteria.
Of the 15 distinct mutations detected, large deletions were detected in 5/15 (33.3%)
patients, including 4/15 (26.7%) partial deletions and 1/15 (6.6%) deletion of the
entire VHL gene by MLPA and the remainder were point mutations detected by
sequencing method, of which five mutations were novel. Using MLPA analysis, we
detected large deletions including both partial deletions and complete gene dele-
tion, which has not been reported in Korean VHL patients. In conclusion, sequen-
tial application of sequencing method and MLPA analysis might make possible to
identify germline mutations in most patients with VHL.
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Accepted : 28 May 2008tients suspicious of VHL disease were referred to Samsung
Medical Center, Seoul, Korea for VHL gene study. Among
them, 15 patients fulfilled the clinical criteria for VHL dis-
ease (Table 1). The VHL disease could be diagnosed on the
basis of clinical criteria in the presence of a single HB, PH,
multiple pancreatic cysts, or RCC in a patient with family
history. For clinical diagnosis of isolated cases of VHL, at
least two HB or a single HB in association with a visceral
manifestation (RCC, PH, or multiple pancreatic cysts) were
required (1, 7). Currently, VHL is subclassified into type 1
and type 2 according to the low or high risk of developing
PH. The Institutional Review Board at Samsung Medical
Center Clinical Research Institute approved this study pro-
tocol, and written informed consent was obtained from each
subject prior to the commencement of this study.
Mutation analysis
Sequencing of the VHL gene
Blood samples were collected from the patients. The genom-
ic DNA was isolated from the peripheral blood leukocytes
using a Wizard genomic DNA purification kit according to
the manufacturer’s instructions (Promega, Madison, WI,
U.S.A.). The three exons of the VHL gene as well as their
flanking introns were amplified using the primer sets designed
by the authors: 1F 5′ AGCGCGTTCCATCCTCTAC 3′ and
1R 5′ GGGCTTCAGACCGTGCTAT 3′ ; 2F 5′ TCCCA-
AAGTGCTGGGATTAC 3′ and 2R 5′ TGGGCTTAAT-
TTTTCAAGTGG 3′ ; 3F 5′ GTTGGCAAAGCCTCTT-
GTTC 3′ and 3R 5′ AAGGAAGGAACCAGTCCTGT 3′ .
A polymerase chain reaction (PCR) was carried out using a
thermal cycler (model 9700; Applied Biosystems, Foster City,
CA, U.S.A.) as follows: 32 cycles of denaturation at 94℃ for
30 sec, annealing at 60℃ for 30 sec, and extension at 72℃
for 30 sec. After treating the amplicon (5 μ L) with 10 U
shrimp alkaline phosphatase and 2 U exonuclease I (USB
Corp., Cleveland, OH, U.S.A.), direct sequencing was per-
formed using the BigDye Terminator Cycle Sequencing
Ready Reaction kit (Applied Biosystems) on an ABI Prism
3100 genetic analyzer (Applied Biosystems). For the patients
identified with mutations, the process of re-PCR and re-
sequencing with alliquot of stored DNA was done. All novel
missense mutations were confirmed by sequencing the 400
control chromosomes.
MLPA analysis
MLPA analysis to detect large deletions in the VHL gene
was carried out using the SALSA P016B VHL probe kit
(MRC-Holland, Amsterdam, Netherlands). The kit contains
eight probes to the VHL gene (four in exon 1 and two in
each of exon 2 and 3), an additional five probes to three other
genes on 3p and two control probes to regions telomeric and
centromeric from VHL, and 14 probes to regions of other
chromosomes. Briefly, 100 ng DNA was denaturated at 98
℃ for 5 min, the MLPA probe cocktail was added to a total
volume of 8 μ L and allowed to hybridize for 16 hr at 60℃.
Following addition of Ligase-65 and ligation at 54℃ for 15
min, the ligase was inactivated at 98℃ for 5 min. PCR pri-
mers, dNTP, and polymerase mix were then added and PCR
was carried out for 33 cycles of (95℃ for 30 sec, 60℃ for
30 sec, and 75℃ for 60 sec). Products were then analyzed
using an ABI PRISM 3130x Genetic Analyzer (Applied Bio-
systems) with ROX-500-labeled internal size standard. Data
was generated using GeneMapper (GeneMapper
� Software
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*, Others include pancreatic neuroendocrine tumors (PNETs), renal and pancreatic cysts and central nervous system tumors; 











history cHB rHB RCC Pheo Others*
1 18/F c.173_174insC Frame-shift
� ++ ---+
2 22/M c.481C>T Nonsense + - +
� ---
3 22/F c.586A>T Nonsense
� ++
� ----
4 24/F c.223_224insT Frame-shift
� ++ + ---
5 27/F c.383T>C Missense
� - + - + - +
6 29/F c.341-?_642+? Large deletion  - + ---+
7 30/F c.484T>C Missense - ++ +
� - +
8 36/M c.341-?_642+? Large deletion  + + - + - +
9 39/M c.486C>G Missense - +
� ---+
10 44/F c.1-?_642+? Large deletion  + + ---+
11 47/F c.217C>T Nonsense + +
� - + - +
12 48/M c.488T>C Missense¢‘ - + - +
� - +
13 49/M c.1-?_463+? Large deletion  + +
� - + --
14 51/M c.464-?_642+? Large deletion  - + - + --
15 52/M c.208G>A Missense  - +
� ----
Table 1. Germline mutations in the VHL gene and related phenotypes in 15 unrelated VHL patientsVersion 4.0, Applied Biosystems). Five healthy control sam-
ples were included in each MLPA test. We determined VHL
gene dosage by using an Excel template offered by manu-
facturer, available at the MRC-Holland web site (www.mrc-
holland. com). Cut-off levels for loss of relative copy num-
bers were set at 0.7 (22).
RESULTS
We were able to define germline VHL mutations in all
patients who fulfilled the clinical criteria for VHL (Table 1).
No mutation of the VHL was detected in other patients who
did not meet the clinical criteria for VHL and mostly had
only RCC or single HB without family history. Sequencing
of the VHL gene detected mutations in 10 patients. In five
patients without mutation by sequencing, four partial dele-
tions and one complete deletion were detected by means of
MLPA (Fig. 1, 2). We observed 10 different intragenic muta-
tions in 10/15 (66.7%) patients: five missense mutations,
three nonsense mutations and two frame-shift mutations.
Four different mutations were found in the second half of
exon 1, one mutation in exon 2, and five mutations in the
5’ part of exon 3. We observed five novel mutations (173_
174insC, 223_224insT, 383T>C, 488T>C, 586A>T) unique
to Korean population. Both novel nonsense (586A>T) and
frameshift (223_224insT, 173_174insC) mutations intro-
duce a premature stop codon leading to a truncated protein
and the missense mutations (383T>C, 488T>C) were not
detected in normal subjects from the Korean population.
Large deletions were detected in 5/15 (33.3%) patients, includ-
ing 4/15 (26.7%) partial deletions and 1/15 (6.6%) deletion
of the entire VHL gene. Partial deletions were heterozygous
in size and position: one removed exon 3, two deletions in-
volved exon 2 and 3 and one deletion involved exon 1 and 2. 
All patients with VHL mutations were classified as type 1
VHL (without PH). Female patient with complete gene dele-
tion, presented with multiple spinal hemangioblastomas
diagnosed at age of 44, which was confirmed by histopathol-
ogy of tumor tissue and upon evaluation of VHL disease,
multiple cysts in pancreas and both kidneys were identified
by abdomen-pelvis CT. Her father was died of RCC and her
younger sister presented with medullary HB at the age of
37 and multiple RCC in both kidneys at the age of 38, har-
bored the same mutation observed in her elder sister, proband.
Seven (46.7%) patients with germline mutations were found
to have no family history of VHL disease. In all cases, sam-
ples from both parents were not available and evidence of de
novo mutations could not further be evaluated.
DISCUSSION
In the present study, we have detected germline VHL muta-
tions in 15/15 (100%) of patients fulfilling the clinical cri-
teria for VHL, in agreement with previous studies (18, 19).
These results imply that most cases fulfilling clinical crite-
ria are related to mutations in the VHL gene and mutation
detection strategies covering all mutation type are necessary
for risk assessment and counseling of patients and their rela-
tives. Many methods are available for the detection of large
deletions in the VHL gene in a diagnostic setting including
long PCR with three overlapping pairs of primers (23), uni-
versal primer quantitative fluorescent multiplex (UPQFM)
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Fig. 1. Multiplex ligation-dependent probe amplification (MLPA) analysis of VHL exons 1-3. Signal intensity reveals only a single copy of
VHL exon 2 and 3 in a patient with VHL due to deletion of VHL exon 2 and 3 (A) and only a single copy of each VHL exon in a patient with
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160 200 240 280 320 360 400 440PCR (24), quantitative Southern analysis (18) and fluores-
cent in situ hybridization (FISH). Recently, another method
for quantitative genomic screening of copy numbers at spe-
cific target sequences has been developed: MLPA (20). In
this study, we used MLPA analysis in the diagnosis of large
deletions of the VHL gene in VHL patients. The identifica-
tion of large deletions of the VHL gene is a crucial point in
order to increase the detection rate of mutations in VHL
patients and to plan the surveillance for early detection of
tumors considering genotype-phenotype correlation. The
obtained results in our study showed MLPA analysis is a sim-
ple rapid reliable tool for the detection of large deletions of
the VHL gene (Fig. 1, 2). MLPA approach involves a reduc-
tion in labor intensity compared with multiplex PCR, quan-
titative Southern analysis and FISH, while showing the supe-
rior sensitivity as these techniques. 
Usually the VHL disease presents with a family history,
but de novo mutations have been reported in as many as 23%
of VHL patients (25). In our study, we could not confirm the
de novo mutations using DNA samples of patients’ parents
but, the maximum 46.7% of patients would be expected to
have de novo mutations. Previous studies showed a frequen-
cy of partial VHL gene deletion of 23-30% and complete
VHL gene deletion in 8-10% in the VHL patients (18, 19,
26). We showed similar results of a frequency of partial dele-
tion and whole gene deletion; approximately 26.7% and
6.6%, respectively. 
The incidence of HB, retinal angioma (RA), RCC and PH
are approximately 93.8%, 18.8%, 50.0%, and 0.0% respec-
tively in our study. In four large previous studies including
83, 152, 215, and 522 individuals, RCCs were recognized
in 14, 28, 37, and 31% of cases, respectively (6, 13, 27, 28).
It was suggested that mutations leading to truncated protein
are more likely to promote renal tumorigenesis than missense
changes, with a 40% increase in the relative risk of harbor-
ing RCC (29) and among VHL families with missense muta-
tions, two mutation cluster regions (MCR-1 and MCR-2)
specifically expose to renal involvement (30). We identified
no considerable genotype-phenotype correlation in VHL
patients with RCC.
Similar mutation associated phenotypes were reported in
VHL families of different origin. Germline mutations pre-
dicted to inactivate the pVHL have been reported to be asso-
ciated with RCCs and CNS HBs without PH (VHL type 1);
germline mutations predicted to produce full length pVHL
to be associated with PH in addition to the other manifesta-
80 H.-J. Cho, C.-S. Ki, and J.-W. Kim
Fig. 2. DNA dosage profiles estimated by MLPA analysis. Ratios on each DNA dosage are plotted relative to single DNA samples from
five unrelated healthy controls. Cut-off levels for loss of relative copy numbers were set at 0.7. A patient with VHL (patient 6) due to dele-
tion of VHL exon 2 and 3 (A) and a patient with VHL (patient 10) due to deletion of whole VHL gene deletion (B). Ex×1, Exon 1; Ex×2,




















































































































































































































































































































































































































































































































0tions of VHL (VHL type 2) (16, 31, 32). Non-missense muta-
tions (10/15, 66.7%) predominated in Korean VHL type 1
patients (Table 1), as in type 1 patients from north America,
Japan, western Europe and Poland (16, 24, 31, 32). Among
missense mutations observed in our patients, 486C>G (C162-
W) was reported in Caucasian type 2 VHL families, but no
member with PH has been found in this patient’s families.
We considered that a large number of affected members and
a longer period of follow up would be necessary for pheno-
typic correlation with this mutation. 
This is the first description of a wide spectrum of germline
VHL mutations including large deletions in Korean VHL
patients. We have contributed five novel germline mutations,
including two missense mutation, two frameshift mutations
and one nonsense mutation. In addition, using MLPA anal-
ysis, we identified large deletion mutations of the VHL, which
did not reported in Korean patients (33) (Table 2) because
of limitation of sequencing technique for the detection of
large deletions. The improved ability to detect germline VHL
mutations primarily reflected the use of MLPA analysis to
detect large deletions of the VHL gene.
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